



**UNICHEM**  
**LABORATORIES LTD.**

December 04, 2023

The Manager – Department of  
Corporate Services  
BSE Limited  
P. J. Towers  
Dalal Street, Fort  
Mumbai – 400001

The Manager – Listing Department

National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C-1, Block G  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400051

Scrip Code : 506690

Symbol : UNICHEMLAB

Dear Sir/Madam,

**SUB: Intimation and disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (“Listing Regulations”)**

This is in continuation of our earlier letter May 10, 2022, wherein it was informed that the Company had sold its strategic investment in Optimus Drugs Private Limited (Optimus) to Sekhmet Pharmaventures Private Limited (Sekhmet) and that the balance 4918 equity shares representing 0.02% holding in Optimus with carrying value of Rs 0.29 crore in the Company’s books of accounts will be sold later in the second tranche.

After satisfaction of necessary conditions precedent, the Company has now sold the said balance equity shares held in Optimus to Sekhmet for an aggregate consideration of Rs 67.47 crores.

This intimation is given under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

In terms of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9 September 2015. Please refer to Annexure I attach herewith for further details in relation to the change in the shareholding from the last disclosure made.

Kindly take the above on record and oblige.

Thanking you.

Yours faithfully

For **UNICHEM LABORATORIES LIMITED**



PRADEEP BHANDARI

**Head – Legal & Company Secretary**



**Annexure I – Part A 1 (ii)(b) Change in the shareholdings from the last disclosure made by the Company: Optimus Drugs Private Limited.**

S. No.	Details required	Information about such event
a)	Name of the target entity, details in brief such as size, turnover etc.	Sale of equity shares held by the Company in Optimus Drugs Private Limited (“ <b>Optimus</b> ”) to Sekhmet Pharmaventures Private Limited.  Total turnover of Optimus (audited): Rs. 1139 crores (22-23)
b)	Whether the <del>acquisition</del> /sale would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being <del>acquired</del> /sold? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No
c)	industry to which the entity being sold/ <del>acquired</del> belongs;	Active pharmaceutical ingredients (“ <b>APIs</b> ”) and intermediates
d)	objects and effects of <del>acquisition</del> /sale (including but not limited to, disclosure of reasons for <del>acquisition</del> /sale of the target entity, if its business is outside the main line of business of the listed entity);	Liquidation of strategic investment by the Company.
e)	brief details of any governmental or regulatory approvals required for the acquisition;	Approval from the Competition Commission of India
f)	The indicative time period for completion of the sale/ <del>acquisition</del> ;	The transfer of shares and sale consideration for 4918 equity shares to Sekhmet representing 0.02% holding in Optimus with carrying value of Rs 0.29 crore in the Company’s books of accounts will be completed by December 4, 2023.





S. No.	Details required	Information about such event
g)	nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration
h)	<del>Cost of sale /acquisition</del> or the price at which the shares are sold/ <del>acquired</del> ;	Rs 67. 47 crores
i)	percentage of shareholding / control sold/ <del>acquired</del> and / or number of shares sold/ <del>acquired</del> ;	Sale of balance 4918 equity shares representing 0.02% equity shares in the Optimus
j)	brief background about the entity sold/ <del>acquired</del> in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Incorporated on December 2, 2003, Optimus is engaged in the business of researching, developing, manufacturing, marketing, and distribution of active pharmaceutical ingredients and intermediates.  Optimus's turnover was Rs 1025 Crores (audited) in 2020-21, Rs. 1123 Crores (audited) in 2021-22 and Rs. 1139 Crore (audited) in 2022-23.

